Gero is a data-driven biotech company. We develop new drugs against aging and other complex diseases using our AI platform. Founders: @fedichev and @geromaxim
Thanks @Nasdaq for celebrating our recent partnership with @chugai_cc to develop novel therapies for age-related diseases. π§¬π§¬
Read the news: https://t.co/PQ96UpeqhJ
Future Fit Asia 2026 was a success! π
Our R&D Director, Michael Winther, represented Gero and joined a panel to discuss current practices that go beyond #GLP-1 therapies to advance #metabolic health.
His main takeaway. β¬οΈ
GLP-1's impact on weight loss and metabolic fitness has spurred efforts to develop novel interventions targeting multiple pathways to promote healthy longevity. However, many nutritional and fitness approaches discussed still arenβt effectively enhancing #longevity.β π
#Lifespan and #healthspan get the headlines. But the real goal is functional span β keeping the ability to think, learn, move, and operate, without decline.
π½οΈ Check out what our Co-founder and CEO, @fedichev, said about functional decline at @jpmorgan 2026.
Most of human aging is thermodynamically irreversible. This is one of the most important β and most disliked β statements in the field.
This means that the goal of extending #lifespan is not rejuvenation, but to stop the clock. β±οΈ
Let me tell you how.
Think of this as the prelude to an imminent new preprint. Read more from our Co-founder and CEO, Peter Fedichev (@fedichev), on his Substack:
https://t.co/KRd2XCJZKe Like, share, and follow for more updates.
A worm at the very end of its life, the equivalent of a human in their 90s. One intervention later, it lives a full second lifetime.
The damage stays exactly where it was. It just stops mattering.
How is that possible?
We've translated the Stability Theory of #Aging into a physics-and-AI #DrugDiscovery platform. Active research and license agreement with Chugai (Roche Group), up to ~$250M in milestones plus royalties on commercial sales, following a prior research collaboration with @Pfizer.